News

A new international initiative, led by scientists at the Frederick National Laboratory for Cancer Research and several other institutions, is being launched to provide expertise and leadership on the development, validation, and standardization of human papillomavirus (HPV) serology assays to be used in vaccine trials. HPV serology assays measure antibody responses following exposure to HPV or HPV vaccines.

More than 100,000 newly diagnosed cases of cancer each year in the United States are subsequently linked to mutations in the KRAS protein. In response to this urgent problem, a new partnership agreement involving the Frederick National Laboratory for Cancer Research (FNLCR) could help identify significant therapeutic opportunities to target these types of cancers.

Before a crowded auditorium of science and business professionals at the Frederick National Laboratory for Cancer Research’s Advanced Technology Research Facility (ATRF), Joost Oppenheim, M.D., had just finished his presentation about a compound that has the potential to expand the impact of a promising category of cancer therapeutics when he fielded a question from Stephan Stern, Ph.D. 

Gene editing using the powerful new CRISPR-Cas9 system is showing promise as a tool for developing potential treatments for inherited diseases, particularly for those caused by single genetic defects.

Biotechnology stakeholders from across the region will have the opportunity to learn about cutting-edge technologies addressing urgent and intractable problems in cancer research at the 2017 Technology Showcase, to be held at the Frederick National Laboratory’s (FNL) Advanced Technology Research Facility (ATRF).

Two government agencies and five national laboratories are collaborating to develop extremely high-performance computing capabilities that will analyze mountains of research and clinical data to improve scientific understanding of cancer, predict drug response, and improve treatments for patients.

For speeding the delivery of an effective candidate vaccine during the largest Ebola outbreak in history, the Frederick National Lab (as Leidos Biomed) was cited along with National Institute of Allergy and Infectious Diseases and GlaxoSmithKline in winning an Excellence in Technology Transfer Award from the Federal Laboratory Consortium for Technology Transfer.

FREDERICK, Md. -- An international collaboration has formed to begin an ambitious program of drug development and testing aimed at treating pancreatic cancers, lung cancers, and other malignancies driven by one of the most common and drug-resistant cancer genes.

Armed with new scientific understanding and the latest technologies, scientists at the Frederick National Lab and Cancer Research UK Beatson Institute in Glasgow, Scotland, will focus on one of the most intractable problems in cancer research — malignancies driven by mutations in RAS genes.

An experimental vaccine for mosquito-borne chikungunya is being tested at sites in the Caribbean as part of a phase II clinical trial being managed by the Frederick National Lab.

Eric Stahlberg, Ph.D., director of high-performance computing at the Frederick National Lab, has been named one of FCW‘s Federal 100 for his work in predictive oncology and his role in the collaboration between the National Cancer Institute and the Department of Energy (DOE) to expand the use of high-performance computing in cancer research.